Papillary Serous Cystadenocarcinoma Research Articles

Value analysis of preoperative peripheral blood LMR in predicting prognosis of serous papillary ovarian adenocarcinoma

ObjectiveTo analyze the predictive effect of preoperative peripheral blood leukocyte related inflammatory indicators on the prognosis of patients with serous papillary ovarian adenocarcinoma.MethodsA retrospective analysis was conducted on the case data of 83 patients with ovarian cancer undergoing tumor cell reduction surgery admitted to our hospital from January 2017 to December 2020. Pathological findings confirmed serous papillary ovarian adenocarcinoma. Kaplan–Meier method was used to analyze the relationship between lymphocyte to monocyte ratio (LMR) and the patients survival prognosis. Analyzing factors affecting patient prognosis which using a multivariable Cox risk.ResultsThe overall survival (OS) of the patients with serous papillary ovarian adenocarcinoma in high LMR group was higher than that in the low LMR group preoperative. The disease free survival (DFS) of ovarian adenocarcinoma patients in the high LMR group was higher than that in the low LMR group preoperative. That was the low LMR indicating a poor prognosis. Single factor analysis showed that age of onset was correlated with OS and DFS, and the body mass index (BMI) was only correlated with OS. Multivariable analysis showed that the age of onset (HR = 2.571, 95% CI 1.199–5.512, P = 0.015) and BMI (HR = 0.337, 95% CI 0.158–0.718, P = 0.005) were independent risk factors for OS.ConclusionsAlthough the serous papillary ovarian adenocarcinoma patients with preoperative peripheral blood LMR reduction have poor prognosis, the correlation between LMR values and prognosis is not significant. Therefore, it is not recommended to use preoperative peripheral leukocyte related inflammatory indicators as prognostic markers for serous papillary ovarian adenocarcinoma.

Ovarian Low-Grade Papillary Serous Cystadenocarcinoma with Osseous Metaplasia- Case Report and Review of Literature

Introduction: The stromal osseous metaplasia is extremely rare finding in serous cystadenocarcinoma of the ovary. Case report: A 45-year old female presented with pain in lower abdomen of about 2 months, breathlessness of 10days. On physical examination per abdomen, a large pelvic mass identified. She had pleural and pericardial effusion. Pericardiocentesis was done. Abdomen and pelvis ultrasound revealed a large heterogeneous right adnexal ovarian mass measuring 13.5 × 13.1 × 10.8cm, volume about 916 ml. It was well defined, oval, cystic, partially solid mass, the impression of ovarian neoplasm was given. There was no significant lymphadenopathy. The left ovary, uterus, cervix, fallopian tubes and rest of abdominal organs were normal. Serum CA 125 was 75.5 U/ml. She underwent total abdominal hysterectomy. On histopathological findings reported as right ovarian low-grade papillary serous cystadenocarcinoma with osseous metaplasia. Conclusion: The osseous metaplasia in ovarian serous cystadenocarcinoma is extremely rare.

Erythroderma-as a paraneoplastic phenomenon of ovarian adenocarcinoma

About 1% of erythroderma cases have a neoplastic or paraneoplastic etiology. But erythroderma secondary to adenocarcinoma of ovary has not yet been reported in the scientific literature to best of our knowledge. A 54-year-old female patient presented to OPD with complaints of reddish itchy scaly lesions over body since 2 months. Based on history and examination, contact dermatitis was considered as provisional diagnosis. Patient was started on prednisolone, cyclosporine and topical corticosteroids which led to partial improvement of the skin lesions. But the lesions recurred and involved almost entire body surface area after 15 days of stopping the medications by the patient. This instigated further evaluation of the patient. All routine lab investigations were within normal limits. Skin biopsy showed mixed inflammatory infiltrate. USG abdo-pelvis detected right ovarian mass. Serum CA 125 was found to be raised. This leads to the suspicion of internal malignancy. Staging laparotomy was done. Tissue biopsy revealed high grade serous papillary cyst adenocarcinoma of right ovary. Thus, final diagnosis of paraneoplastic erythroderma secondary to ovarian adenocarcinoma was made. Patient responded well to corticosteroids after total abdominal hysterosalphingo-oophorectomy and chemotherapy in due course of time of 4 months. Hence, we conclude, erythroderma patients with unclear etiologies should be thoroughly evaluated. This will lead to timely diagnosis and treatment leading to better prognosis.

Development and identification of a prognostic nomogram model for patients with mixed cell adenocarcinoma of the ovary

BackgroundMixed cell ovarian adenocarcinoma (MCOA) is a malignant gynecologic tumor consisting of serous, mucous, and papillary tumor cells. However, the clinical features and prognosis of MCOA patients are unclear.MethodsIn this study, univariate and multivariate Cox proportional risk models were performed to identify independent prognostic factors. The Kaplan–Meier method was used to assess the relationship between clinical characteristics and patient survival. Finally, a nomogram was constructed and validated to predict patient survival time, and the C-index was used to evaluate the efficacy of the nomogram.ResultsA total of 2,818 patients diagnosed with MCOA were identified, and the 5-year survival rate was 62%. Univariate and multivariate Cox models suggested that age (HR=1.28, 95% CI[1.15,1.44]), grade (HR=1.26, 95% CI[1.12,1.41]), SEER stage (HR=1.63, 95% CI[1.25,2.13]) and AJCC (American Joint Committee on Cancer) stage (HR=1.59, 95% CI[1.36,1.86]) were independent prognostic factors for MCOA patients. After propensity score matching for age, grade, SEER stage, and AJCC stage, the 5-year survival rate was 69.7% for ovarian serous cystadenocarcinoma and 62.9% for ovarian papillary serous cystadenocarcinoma. These results mean that serous adenocarcinoma had the best prognosis of the three pathologic types of ovarian carcinoma (p<0.0001), with no significant difference between papillary serous cystadenocarcinoma and MCOA (p=0.712). Finally, a nomogram consisting of age, grade, SEER stage, and AJCC stage was established and validated to predict the survival time, with C-indices of 0.743 and 0.731, respectively.ConclusionsIn summary, MCOA is uncommon, and age, grade, SEER stage, and AJCC stage are independent prognostic factors. Compared with other common malignant ovarian tumors, MCOA has a poor prognosis.

Recurrent liver metastasis in ovarian cancer

The most common sites of metastasis in ovarian cancer is liver, peritoneum, and lymph nodes resulting from hematogenous spread or secondary to liver parenchymal invasion from perihepatic peritoneal metastases. The case was retrieved from routine reporting at our hospital. A 34-year-old female presented with lump in left side of abdomen for six months. Ultrasonography showed Left complex tubo-ovarian mass. Serum level of CA125 was 19.8U/mL. Upfront surgery was done. Histopathology showed malignant lesion, positive for WT1, P53 & CK7 and negative for CK 20. Retroperitoneal lymph nodes and omentum were involved. The cases was diagnosed as epithelial ovarian cancer, high grade papillary serous cyst adenocarcinoma stage III. Three months after surgery repeat contrast enhanced computed tomography showed lung and liver metastasis lymphadenopathy. Patient was given 6 cycles of paclitaxel + carboplatin to achieve complete clinical response (CR). Lesions of lung, liver & lymph node subsided. She spent 33 months of treatment free interval, after which lymph node enlargement was noticed and its fine needle aspiration cytology showed metastasis. Patient was put on to oral metronomic therapy with etoposide, cyclophosphamide, and celecoxib (COX-2 inhibitor) for 8 months, which showed CR. Again after 4 months, lesion in liver reappeared with raised CA 125, suggesting second relapse. The patient is on oral metronomic therapy till date with improved clinical condition. This study highlights the need of early diagnosis, adjuvant chemotherapy with frequent follow up in this case. Liver is an early site for metastasis. Second relapse in also not uncommon.

Evaluation of the Potential Diagnostic Utility of the Determination of Selected Caspases-Markers Involved in the Regulation of Apoptosis-In Patients with Ovarian Cancer.

Ovarian cancer remains a major diagnostic and therapeutic problem in modern gynecological oncology. For this reason, research which focuses on the search for new diagnostic markers and the assessment of their possible usefulness in clinical practice is still being conducted. The aim of this study was to evaluate serum levels of caspase-3, caspase-8, and caspase-9 in women with ovarian cancer. Patients with ovarian serous cystadenoma (Cystadenoma serosum) and papillary serous cystadenocarcinoma (Cystadenocarcinoma papillare serosum IIIC) were included in the study, as well as healthy women who constituted the control group. The results of the study revealed a statistically significantly decreased mean serum levels of caspase-3, caspase-8, and caspase-9 in women with ovarian cancer as compared to the control group (p ˂ 0.001), which indicates the involvement of the studied parameters in immune system disturbances occurring in the process of apoptosis by the extrinsic and intrinsic pathway and may be one of the mechanisms of immunosuppression accompanying these tumors. Determination of serum levels of examined caspases and CA 125 antigen in women with ovarian cancer in combination with other markers may prove useful in the future in the diagnosis of ovarian cancer, but this requires further studies.

Comparative Study of Ultrasound and Magnetic Resonance Imaging of Adnexal Masses

Background: Current study aimed to assess the role of ultrasound and MRI in the evaluation of adnexal mass lesions and comparison with clinical outcomes. Subjects &amp; Methods: A total of 30 suspected adnexal mass detected on ultrasonography was performed MRI, and accuracy of both USG and MRI were compared with histopathology. Results: Abdominal pain was predominantly confined to the lower abdomen in13 of 30 cases (43.3%). On USG total number of benign lesions was 19, and the total number of malignancies was 11. However, on MRI, 21 cases were mild, and 9 cases were malignant. six cases were diagnosed as malignant in ultrasound. In these six cases, two cases were serous cystadenocarcinoma, two were mucinous cystadenocarcinoma, one was serious papillary cystadenocarcinoma of the fallopian tube, and one was a malignant tubo-ovarian mass. MRI accurately diagnosed 4 indeterminate cases that correlated with the histopathology report. 9 malignant lesions were diagnosed as malignant by MRI were 3 cases of serous cystadenocarcinoma, 2 cases of mucinous cystadenocarcinoma, 1 case of malignant tubo-ovarian mass, 1 case of endometrioid carcinoma, 1 case of serous papillary cystadenocarcinoma of the fallopian tube and 2 cases of malignant sex cord-stromal neoplasms. Both the cases of serous cystadenomas were correctly diagnosed as benign lesions on both ultrasound and MRI. There were 2 cases of mucinous cystadenocarcinoma, which were accurately diagnosed as malignant on both USG and MRI due to the presence of solid components, mural thickening. The sensitivity, specificity, and accuracy of USG were 36.6%, 94% and 55% respectively. The sensitivity, specificity, and accuracy of MRI were 81.80%, 94.7%, and 65.7%, respectively. Conclusion: The best agreement was observed between MR findings and diagnosis in origin, tissue content, and tissue characteristics. Sonography had a weak correlation in context to the definitive diagnosis for the origin and tissue content of a mass.

Histopathological spectrum of cystic ovarian mass- A one year study

Introduction: Ovarian cyst are fluid filled sacs that form within or on the ovary, which can either be non neoplastic or neoplastic. Non neoplastic cyst can be physiologic or pathologic and are more common than neoplastic cyst. This study was undertaken retrospectively for a period of 1 year to determine the histopathological spectrum of ovarian cystic lesions in our hospital. Result: During the study period 120 cases presenting with ovarian cystic masses were seen. The age range of patient was from 15 to 60 years. Maximum number of cases were seen in the age group of 21-30 years. Non neoplastic cyst were the most common among all the lesion studied of which follicular cyst (53.3%) made majority of cases. Among the Neoplastic lesion, 83% were benign tumours followed by malignant tumours (13%) whereas borderline tumours were found in 3% only. Serous cystadenoma (21%) were the most common benign tumour whereas serous papillary cystadenocarcinoma (62.5%) was the most common among the malignant cystic lesion. Most common clinical presentation was abdominopelvic mass (60%). Conclusion: Ovarian cystic lesions are commonly encountered surgical specimens. Abdominopelvic mass is the predominant clinical feature. Histopathological examination is important to categorize them into neoplastic and non neoplastic lesion so that proper treatment could be given to the patients. Keywords: Ovarian, Neoplastic, Benign, Malignant.

NFAT Overexpression Correlates with CA72-4 and Poor Prognosis of Ovarian Clear-Cell Carcinoma Subtype.

Current biomarkers did not overcome the limitations of clinical application due to the heterogeneity of ovarian tumors. The role of nuclear factor of activated T cells (NFAT) in the prognosis of different histological subtypes of ovarian cancer remains unclear. NFAT expression was analyzed in 302 ovarian tumors from The Cancer Genome Atlas (TCGA) dataset and was further confirmed by 88 ovarian tumor specimens, including 30 clear-cell carcinoma, 34 serous carcinoma, and 24 papillary serous cystadenocarcinoma. The correlations between NFAT expression, cancer biomarkers, and clinical characteristics in different subtypes of ovarian tumors were analyzed. ALGGEN PROMO, reporter assay, and NFAT overexpression and knockdown were used to identify chondroadherin (CHAD) as the downstream target of NFAT. NFAT was significantly upregulated only in late-stage clear-cell carcinoma, but not in other two subtypes. NFAT levels were correlated with CA72-4 levels and poor overall survival and disease-free survival (P < 0.05), suggesting that NFAT together with CA72-4 were specific prognostic markers for clear-cell carcinoma. Pathological stage and lymph node metastasis were the prognostic factors affecting serous carcinoma (P < 0.05), while CA-125 was the prognostic factor affecting papillary serous cystadenocarcinoma (P < 0.05). PROMO and reporter assay indicated that CHAD was the downstream target of NFAT. In addition, NFAT overexpression and silencing increased and reduced CHAD expression, respectively. NFAT together with CA72-4 were specific tumor markers for risk assessment of unique clear-cell subtype of ovarian tumors. CHAD was identified as the downstream target gene of NAFT and was associated with poor survival of ovarian cancer.

Bilateral ovarian carcinoma with colorectal metastases - An unusual presentation

Primary ovarian carcinoma may metastasize to the peritoneum leading to malignant ascites. Four percent cases of primary ovarian carcinoma can involve the colorectum. We present a case report of a 50-year-old women who had complaints of bilateral adnexal mass and disturbed menstruation with altered bowel habits. Computed tomography scan of the abdomen and pelvis showed a bilaterally enlarged ovaries and a lobular rectal mass. Proctoscopy substantiated the rectal mass as an ulcerated lesion. Histopathology confirmed the diagnosis as bilateral serous papillary cystadenocarcinoma. Left hemicolectomy specimen illustrated foci of atypical glands. Immunohistochemical staining of both the tumor masses showed strong cytokeratin 7 positivity with negative cytokeratin 20 expression. Bilateral involvement of the ovaries with colorectal metastasis is very uncommon, which is highlighted in this paper. Keywords: Bilateral, Cancer, Colorectum, Immunohistochemistry, Ovary, Metastasis.

Outcomes of surgical resection for pulmonary metastasis from ovarian cancer

BackgroundDue to its rarity, information on pulmonary metastasectomy for pulmonary metastasis from ovarian cancer is limited.MethodsCases of pulmonary metastasectomy for ovarian cancer were collected in a multi-institutional setting and the outcomes were analyzed.ResultsAmong 1508 cases in which pulmonary resection was performed to treat pulmonary metastasis from tumors of various organs, 6 cases (0.4%) involved pulmonary metastasis from ovarian cancer. The mean age was 61 years (range, 39–75 years). The histological types were undifferentiated carcinoma in 2 patients, and clear cell adenocarcinoma, serous papillary cystadenocarcinoma, serous adenocarcinoma, and endometroid adenocarcinoma in 1 patient each. One patient (17%) had a history of liver metastasis at the time of pulmonary resection. The median disease-free interval was 22 months (range, 0 [synchronous]-188 months). The tumor was solitary in 5 patients (83%). The mean tumor size was 15 mm (range, 5–23 mm). All 6 patients underwent complete resection. The type of resection was wide wedge resection in 3 patients, segmentectomy in 2 patients, and lobectomy in 1 patient. Four patients (67%) received postoperative chemotherapy. Thus far, 4 patients (67%) have experienced recurrence after pulmonary resection. In terms of outcomes, 1 patient who had synchronous pulmonary metastasis with the primary tumor died in the early period after pulmonary resection, 1 patient is alive without recurrence after a short follow-up period (5 months), 3 patients have achieved mid- to long-term survival and are alive with disease (38–61 months), and 1 patient achieved long-term (61 months) disease-free survival.ConclusionsPatients with pulmonary metastasis from ovarian cancer who fulfill the eligibility criteria for pulmonary metastasectomy are rare. Pulmonary metastasectomy for ovarian cancer can provide favorable outcomes in highly selected patients. Patients with synchronous pulmonary metastasis from ovarian cancer are not good candidates for pulmonary metastasectomy.

Histopathological study of ovarian tumors in a tertiary care center

Introduction: Ovary is a complex structure and its neoplasms show a wide spectrum of histological types and clinical behavior. The present study was done with the aim of studying the histopathological pattern of ovarian tumors in women of various age groups. Ovarian tumors represent about 30% of all cancers of the female genital system. Ovarian tumor is the seventh leading cause of cancer death. Ovarian tumors are often difficult to detect until they are advanced in stage or size, as symptoms are vague and insidious. An accurate and early diagnosis of malignant lesions will go a long way in the optimal management of these cases. Aims and Objectives: To determine the frequency of different histological types of ovarian tumors in a tertiary care center. Materials and Methods: This was a retrospective study included 150 cases of histopathologically proven ovarian tumors, reported in the Sree Mookambika Institute of medical sciences, over a one and half year period (January 2018 to June 2019). These were classified according to the WHO classification of ovarian tumors. Clinical presentation of the patients was analyzed from archived case records. Results: Of 150 cases of ovarian tumors, 138 masses were unilateral (92%) and 12 were bilateral (8%). Benign neoplastic lesions were 58.7%, and malignant was 2%.In benign neoplastic, the most common neoplasm was serous cystadenoma followed by mucinous cystadenoma In malignant, the current study had 2 cases of mucinous cystadenoma with borderline malignancy and 1 case was serous papillary cystadenocarcinoma Conclusion: A more detailed prospective study include genetic profiling, to establish the reason for this low incidence of malignant lesions

A case report of rare synchronous primary cancer in genital tract of middle aged female: Synchronous primary endometrial adenocarcinoma and serous papillary cystadenocarcinoma of ovary.

Synchronous cancers are defined as two or more histologically distinct malignancies arising in the same site, following each other in a sequence of &lt; 2 months. Synchronous primary cancers are rare in general population and account for only 0.5-1.7% of gynaecological malignancies.1,2 It is important to distinguish synchronous primary tumors from metastatic malignancies.3 Case Report: We report a case of 55 years old female with history of pain in abdomen for the last one year. Surgical intervention was planned after complete work up. Hysterectomy with bilateral salpingo-oophorectomy and omentectomy was done. Histopathological examination reported the presence of synchronous endometrial adenocarcinoma well differentiated and malignant ovarian tumor low grade serous papillary cystadenocarcinoma. Conclusion: Though a rare presentation synchronous primary endometrial and ovarian cancers, usually identified at early stage and have a good prognosis.

Higher expression of calcineurin predicts poor prognosis in unique subtype of ovarian cancer

BackgroundThe role of calcineurin/NFAT signaling in ovarian cancer has been unknown. NFAT was significantly overexpressed in ovarian cancer tissues and that overexpression of NFAT was significantly associated with metastasis and poor prognosis on clinical tissue level. To investigate whether NFAT upstream protein, calcineurin (CN), affects the prognosis in various histological subtype of ovarian cancer (OC).MethodsThe association between CN and clinical features was analyzed in 50 OC patients treated from 2007 to 2012. CN expression was examined using immunohistochemistry. We observed the association of CN expression with the prognosis in these patients.ResultsCN expression was significantly increased in later-stage tumor tissue of serous carcinoma compared with those with early-stage. The expression of CN positively correlated with the serum cancer antigen 125 (CA125) level in ovarian clear-cell carcinoma and the serum alpha-fetoprotein (AFP) level in papillary serous cystadenocarcinoma. Particularly, higher CN expression in tumor tissues significantly correlated with reduced overall survival among patients with serous carcinoma. In addition, the serum cancer antigen 72–4 (CA72–4) level, serum carcinoembryonic antigen (CEA) levels, pathological stage, lymph node metastasis, and chemotherapeutic resistance were identified as significant prognostic factors in ovarian clear-cell carcinoma, serous carcinoma, or papillary serous cystadenocarcinoma.ConclusionsCN is upregulated in ovarian cancer tissues with later-stage and that the expression of CN, CA72–4, and CEA was remarkably associated with poor prognosis in unique subtype of ovarian cancer. CN levels may be investigated for use as a prognostic biomarker for risk assessment in unique subtype of OC patients.

MiR-182-5p inhibited proliferation and migration of ovarian cancer cells by targeting BNIP3.

To investigate the potential effect of microRNA-182-5p (miR-182-5p) on the development of ovarian cancer (OC) and the relevant mechanism. The expression levels of miR-182-5p in OC tissues and paracancerous normal tissues were detected. The miR-182-5p expression in OC cells and ovarian epithelial cells was also determined. Through online prediction (TargetScan, miRDB), the potential target of miR-182-5p was screened and further confirmed by the Luciferase reporter gene assay. The effects of the miR-182-5p on human ovarian serous papillary cystadenocarcinoma cell line (SKOV3) cells were determined by in vitro experiments. The low expression of miR-182-5p in OC was confirmed by quantitative Reverse Transcription-Polymerase Chain Reaction (qRT-PCR) assay. BCL2/adenovirus E1B 19 kDa protein-interacting protein 3 (BNIP3) was identified as a direct target of miR-182-5p. Subsequent experiments showed that the BNIP3 knockdown resulting from the up-regulation of miR-182-5p inhibited cell proliferation, clone formation and migration ability of OC cells. Our research showed the inhibitory function of miR-182-5p in OC by targeting BNIP3, thus providing an experimental basis for the treatment of OC.

Clinical and histopathological features of ovarian cancer in Rizgary Hospital/Erbil City from 2014 to 2017

Background: Ovarian cancer is a heterogeneous disease with variations in clinical behavior and outcome. It is a group of many subtypes with distinct biological features that lead to differences in response to treatments, recurrence rates, and survival. Objective: The aim of the study is to describe the epidemiology of the diagnosed cases of ovarian cancer from 2014 to 2017 in Erbil, Iraq. Materials and Methods: This is a retrospective study, 100 ovarian cancer cases were reviewed from Rizgary Oncology Center in Erbil. Then, we compared histological types with age groups of the study as premenopausal and postmenopausal, stage of the disease, grade, and with side of tumor. Furthermore, this study includes the most important risk factors that may affect the incidence of ovarian cancer which includes menarche age, age of menopause, and with obesity. Results: The result showed that ovarian cancer occurs in old age groups with a percentage of 64%. The most common type is epithelial ovarian cancer with subtype papillary serous adenocarcinoma in 56%, with all types, the most affected site is the right one in a percent of 57%. Grade 3 is the dominant one at presentation in a percent of 49%. About staging at the time of diagnosis, Stage 4 presented in a percent of 58%, and 16% of patients were obese. Conclusion: Most common type of cancer is epithelial type of papillary serous cystadenocarcinoma histology that occur in old patients and presented in advanced stage at the time of diagnosis with poor differentiation, and the most effective treatment is total abdominal hysterectomy + bilateral salpingo-oophorectomy followed by adjuvant platinum-based chemotherapy.

258 - Single-Site Laparoscopic Interval Debulking Surgery for Late Stage Ovarian Cancer

A lady, aged 45, the pathological findings by MRI directed biopsy was High Grade Ovarian Serous Papillary Cystadenocarcinoma with Omentum involved.

Supernumerary Ovary: A Case Report

Supernumerary Ovary is a rare incidental diagnosis, which is on the rise due to modern imaging modalities and advent of laparoscopy in Gynecology. It has various clinical implications. It can present like Endometrioma, Fibroma or as papillary serous cystadenocarcinoma. Removal of this additional ovary tends to stay in dilemma, because its follicles can be used in the treatment of infertility and it has malignant potential. Hence, correct diagnosis and prompt decision making is necessary based on the patient age and parity. As in our case, a nulligravida presented with torsion of the ovarian cyst. During Laparoscopic procedure, we noticed that this pathology was from the third ovary as in this case Supernumerary ovary. The removal of the ovary was not done as this patient was undergoing treatment for infertility. Weighing the benefits over risks, patient was counselled for proper follow-up and removal of this Supernumerary ovary following completion of family. All gynecologists should be aware of this rare condition due to its clinical implications and its appropriate management. Keywords: Supernumerary Ovary, Ovarian Torsion, Malignant potential, Fertility, Incidental diagnosis

Features of ovarian Brenner tumors: Experience of a single tertiary center.

Objective:Brenner tumors are rare neoplasms of the ovary. The aim of this study was to investigate the clinical features of Brenner tumors.Materials and Methods:The clinical features of 22 patients who were treated in Ankara University Faculty of Medicine Obstetrics and Gynecology Department between 2005 and 2015 were evaluated retrospectively from hospital medical records.Results:The patients were aged 34 to 79 years at the time of diagnosis and the mean age was 55.1 years. Two (9.1%) patients were pre-menopausal, five (22.7%) were peri-menopausal, and 25 (68.2%) patients were postmenopausal. One patient was pregnant. Twenty of the neoplasms were benign, one was malignant, and one was both malignant and benign. There was no recurrence in the malignant cases. Six (27.2%) patients had mixed tumors consisting of Brenner tumor and another ovarian pathology. Specifically, the other component of these tumors was mucinous cystadenoma in four patients, endometriosis externa in one patient, and high-grade serous papillary cyst adenocarcinoma in one patient.Conclusion:Brenner tumors are usually incidental benign pathologic findings of surgical procedures in postmenopausal women. They can be found with other ovarian pathologies such as mucinous ovarian tumors and can coexist with other female genital tumors. Further studies are needed to completely understand the clinical features of Brenner tumors.

Neoplastic and Nonneoplastic Cystic Diseases of the Ovary: A Three-Year Prospective Study in a Tertiary-Care Center in Southern India

Objectives: The aim of this study was to determine the distribution of morphologic patterns of neoplastic and nonneoplastic cystic ovarian lesions, and their distribution in different age groups in a tertiary-care center in Southern India. Materials and Methods: This was a prospective study of all cystic ovarian lesions diagnosed during a period of 3 years. Results: There was a total 303 cases of cystic ovarian lesions, of which 232 cases were neoplastic. Of the neoplastic lesions, benign tumors comprised 214 cases, borderline tumors 5 cases, and malignant tumors 13 cases. Of 232 cases having neoplastic lesions, 26 were associated with various nonneoplastic lesions as well. Surface epithelial tumors emerged as the most common, accounting for 190 cases (81.90%); followed by germ-cell tumors, with 40 cases (17.24%); and sex-cord stromal tumors being least common, with 2 cases (0.86%). Among the malignant tumors, immature teratoma was the commonest type, with 4 cases (30.77%); followed by papillary serous cyst adenocarcinomas, with 3 cases (23.08%). Conclusions: Cystic lesions of the ovary should be evaluated histologically to decide the future course of management. Cystic ovarian tumors were found to occur in wide range of ages (from 8 days to 76 years). Compared to the U.S. population (13%–21%), the distribution of malignant ovarian tumors in cystic lesions in this study (5.6%) was lower. (J GYNECOL SURG 32:263)